Picture Demy-Colton BioFuture 2021 NYC C Virtual Option 650x80px

Organisation › Details

Gilead Sciences (Group)

https://www.gilead.com

	Start	1987-06-22 established
	Industry	biopharmaceutical
	Industry 2	virostatic agent

	Street	333 Lakeside Drive
	City	94404 Foster City, CA
		Address record changed: 2020-12-02

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	22,449,000,000 (revenues, total, consolidated (2019) 2019-12-31)
	Profit	5,364,000,000 (2019-12-31)
	Cash	25,840,000,000 (2019-12-31)


		Record changed: 2020-03-11

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Gilead Sciences (Group)

[1] BioNTech SE. (7/19/21). "Press Release: BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD". Mainz & Santo Monica, CA....
[2] Galapagos N.V.. (2/10/21). "Press Release: Galapagos and Gilead Discontinue ISABELA Phase 3 Trials in IPF". Foster City, CA & Mechelen....
[3] Gilead Sciences, Inc.. (1/6/21). "Press Release: Kite and Oxford BioTherapeutics Establish Cell Therapy Research Collaboration in Blood Cancers and Solid Tumors". Santa Monica, CA, Oxford & San Jose, CA....
[4] Ori Biotech Ltd.. (12/15/20). "Press Release: Ori Biotech Adds to Its World-Class Team". London & Woodcliff Lake, NJ....
[5] Galapagos N.V.. (12/15/20). "Press Release: Gilead and Galapagos Announce New Commercialization and Development Agreement for Jyseleca (filgotinib)". Foster City, CA & Mechelen....
[6] Gilead Sciences, Inc.. (12/10/20). "Press Release: Gilead Sciences to Acquire MYR GmbH". Foster City, CA & Bad Homburg....
[7] Gilead Sciences, Inc.. (10/23/20). "Press Release: Gilead Sciences Completes Acquisition of Immunomedics, Inc.". Foster City, CA....
[8] ProteoNic B.V.. (10/20/20). "Press Release: ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics". Leiden....
[9] Gilead Sciences, Inc.. (9/13/20). "Press Release: Gilead Sciences to Acquire Immunomedics". Foster City, CA & Morris Plains, NJ....
[10] Galapagos N.V.. (8/19/20). "Press Release: Galapagos Announces that Gilead Received a Complete Response Letter for Filgotinib for the Treatment of Moderately to Severely Active Rheumatoid Arthritis". Mechelen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]